在ALS/FTLD中,上下文依赖交互器调节TDP-43功能障碍
bioRxiv : the preprint server for biology
|April 28, 2025
概括
TDP-43蛋白质功能障碍驱动神经退行性疾病,如ALS和FTLD. 这项研究揭示了TDP-43错位化如何破坏拼接,并确定了关键调节者,提供了潜在的治疗点.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- TDP-43蛋白质功能障碍是肌缩侧面硬化 (ALS),前叶退化 (FTLD) 和临主导的与年龄相关的TDP-43脑病变-神经病变 (LATE-NC) 的关键特征.
- 导致TDP-43功能障碍的确切机制,包括其错误定位和聚合,尚未完全理解.
- 了解TDP-43的细胞环境和相互作用对于开发有效治疗这些破坏性神经系统疾病至关重要.
研究的目的:
- 在模仿神经退行性疾病病理的条件下研究TDP-43的上下文依赖相互作用.
- 识别涉及TDP-43错位化,聚合和功能丧失的新型蛋白质和途径.
- 为了发现TDP-43蛋白病变的潜在治疗点.
主要方法:
- 利用APEX2驱动的近距离标签与质谱相结合,在特定的细胞环境中绘制TDP-43互动组图.
- 综合单核RNA测序 (snRNA-seq) 来自ALS和FTLD患者的数据,以确定与疾病相关的分子变化.
- 进行功能查以验证已识别的TDP-43调节器并评估它们对TDP-43功能的影响.
主要成果:
- 确定了TDP-43的上下文依赖相互作用体,揭示了与拼接因子的破坏性关联和改变的生物分子凝聚物动态.
- 已经证明,核光斑完整性受损,特别是通过SRRM2下调,促进了TDP-43的错误定位和功能丧失.
- 发现NUFIP2作为TDP-43相互作用体,将蛋白质隔离成细胞质聚合物,并在患者组织中与病理共同定位.
- 突出了HNRNPC作为TDP-43介导拼接的关键调节器,表明调节任何一种蛋白质可以纠正异常拼接事件.
结论:
- 破坏核斑完整性和改变的蛋白质相互作用,如NUFIP2和HNRNPC,是驱动神经退行症TDP-43功能障碍的关键机制.
- 这些发现为TDP-43蛋白质病变提供了关键的机制性见解.
- 确定了特定的蛋白质和途径作为ALS,FTLD和LATE-NC的潜在治疗点.
更多相关视频
06:58Evaluation of LC3-II Release via Extracellular Vesicles in Relation to the Accumulation of Intracellular LC3-positive Vesicles
Published on: October 18, 2024
530
13:31Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis
Published on: February 12, 2015
8.7K
相关概念视频
Alzheimer's Disease: Overview
315
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
315
Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
Long-term Depression
2.4K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.4K
Neural Regulation
39.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K
